Accelr8 Technology Corporation has announced that BD (Becton, Dickinson and Company) and Accelr8 have agreed in principle to terms for an agreement with respect to Accelr8’s BACcel™ rapid bacterial diagnostic system.
Under the contemplated agreement, BD will fund an 18-month milestone project starting April 1, 2008. BD will also have the option to license the technology for product development, manufacturing and commercialization for the clinical diagnosis of infectious diseases.
The definitive agreement is expected to be signed before April 30, 2008.
According to David Howson, Accelr8’s president, “BD leads the industry in clinical microbiology, with broad product offerings for classical microbiology as well as molecular diagnostics. We are excited to work with BD as we move into our next phase of BACcel development.”
In other news, Accelr8 noted issuance of its core “Quantum Microbiology™” patent, for which the company previously had announced notice of allowance. Additionally, the company noted acceptance of three scientific presentations for the 108th General Meeting of the American Society for Microbiology to be held June 1-5 in Boston, MA. Subjects to be covered include multiplexed identification of multiple drug resistance mechanisms, rapid Acinetobacter immunoassay performance, and quantitative analysis of bacteria extracted directly from human clinical specimens.